The future of the BIOSECURE Act was made more uncertain over the weekend after senators left the legislation out of a pivotal defence budget bill. The omission means the act, which intends to ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation created a window of reprieve for the affected biotech companies.

Based on recent policy signals and statements from incoming administration officials, a picture of potential regulatory and policy changes that ...

During a Senate HELP Committee hearing, Robert F. Kennedy Jr. stated that President Trump is dedicated to bringing drug ...

The BIOSECURE Act, which will prohibit businesses in the US from contracting with various Chinese firms on national security grounds, has not been included in a defence budget bill viewed as ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

Ascentage is looking to use the IPO proceeds to advance its Phase III candidates for chronic or small lymphocytic leukemia ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

With potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a sizable ...